Key Data on Improving Outcomes in HF Patients

2016 ESC HF Guidelines

Maximize RAAS Inhibitor Dose to Achieve Greatest Benefit

2016 ESC HF Guidelines (cont)

Definitions of HF: LVEF Criteria

HF Outcomes

Sacubitril/Valsartan, an ARNI, Mechanism of Action

ACE Inhibitor vs ARNI

PARADIGM-HF Study Design

Benefit of ARNI in HFrEF: Results of the PARADIGM-HF Trial

Benefit of ARNI in HFrEF: Results of the PARADIGM-HF Trial (cont)

Evidence-Based Guidelines: Use of Sacubitril/Valsartan

Dual Blockade of the RAAS

Sacubitril/Valsartan in HFrEF: Patient Monitoring

Sacubitril/Valsartan in HFrEF: Starting Dose and Dose Titration

Ivabradine Mechanism of Action

SHIFT Trial: Study Methods

SHIFT Trial: Treatment at Randomization

SHIFT: Ivabradine vs Placebo in Patients With Chronic HF

SHIFT: Overall Safety and Tolerability

Use of Ivabradine in Patients With HF and AF

SHIFT: Select AEs

Effects of Ivabradine on LV Remodeling and Function: SHIFT Echocardiography Substudy

Ivabradine and HRQoL: Results From the SHIFT Study

Trials With Sacubitril/Valsartan in Patients Following An Episode of ADHF

PIONEER-HF: Study Methods

PIONEER-HF: Change in NT-proBNP Concentration Over Time (Primary Endpoint)

PIONEER-HF: Additional Outcomes

TRANSITION: Study Design

TRANSITION: Important Observations

Use of Sacubitril/Valsartan: 2019 ESC Clinical Practice Update

Are Revisions to the Guidelines Regarding Sacubitril/Valsartan Use Warranted?

ARNI Use in Patients With HFrEF: Things To Consider

Hospitalization for Acute HF

Pre-Discharge Initiation of Ivabradine Following an Episode of ADHF?

Program Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)